20
Participants
Start Date
November 28, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
May 31, 2027
ART
ART is a combination of three or more drugs from different classes of antiretroviral medication.
10E8.4/iMab
10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
VRC07-523LS
VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
National Institute for Medical Research-Mbeya Medical Resarch Center, Mbeya
Henry M. Jackson Foundation for the Advancement of Military Medicine
OTHER
US Military HIV Research Program
NETWORK
National Institute of Allergy and infectious Diseases (NIAID)/Vaccine Research Center (VRC)
UNKNOWN
David Ho
OTHER